Our miRNAs platform try to find new ways to develop therapies against metabolic diseases. Our products have been engineered to change the proteome for specific metabolic enhancing.
Currently, the tumor-targeting strategy for MV is further developed by taking advantage of microRNA techniques (“Targeting 2.0”). We have know-how to introduce MicroRNA synthetic sequences in the viral genome.
Today, our main project is to develop a miRNA against the Cushing syndrome and dysfunctional lipid homeostasis, and drugs who enhance the insulin sensivity.
We try to find new pathways to enhance the chemosensitivity in tumors.